Wayne I. Roe

ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Entrack, Inc. specializes in the development of novel treatment solutions for the diagnosis and treatment of gastrointestinal diseases. The firm operates as a medical technology venture company, with focus on the development of gastric stimulators for the treatment of obesity-related conditions and disorders. The company was founded in 2001 and is headquartered in San Jose, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA.

ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.